Vaccines for Newest Pandemic Flu Threat to be Tested at Emory in National Effort
Sep 18, 2013 - 6:13:31 PM
The National Institute of Allergy and Infectious Diseases of the National Institutes of Health is sponsoring the clinical trial through the Emory Vaccine and Treatment Evaluation Unit (VTEU) and seven other VTEUs around the country. The Emory clinical trial will be conducted at the Emory Vaccine Center's Hope Clinic in nearby Decatur, and at the Emory Children's Center Vaccine Research Clinic.
"This bird flu vaccine trial is extremely important, because humans have not developed any immunity to this newly identified H7N9 virus. By preparing for a potential outbreak through a tested vaccine, we hope to reduce the potentially severe impact of a future pandemic. We also expect to learn more about flu vaccines, how they induce immunity, and the most effective doses in different age groups," says Mark J. Mulligan, MD, professor of medicine in Emory University School of Medicine and executive director of the Hope Clinic.
The new avian influenza strain was first detected in China last spring in 135 people, most of whom had contact with poultry. Most people had severe respiratory infections, and 44 people - or 32 percent of those who were ill - died. While the median age of those stricken with the H7N9 flu was 58, four cases were confirmed in children.
"Although the H7N9 influenza virus has not spread easily between people and has not yet been detected in the United States, there is concern that this could change and potentially it then could develop into a global pandemic," says Paul Spearman, MD, chief research officer for Children's Healthcare of Atlanta and Nahmias-Schinazi Professor and vice chair of research in the Department of Pediatrics, Emory School of Medicine.
The clinical trial will enroll up to 700 healthy adults nationally 19 to 64 years old. At Emory, researchers expect to enroll approximately 175 volunteers at the Hope Clinic and at the Emory Children's Center (ECC), with support from Children's Healthcare of Atlanta through its partnership with Emory if future studies in younger age groups are needed.
Participants will receive different dosages of an investigational vaccine given with an adjuvant - a substance added to a vaccine to increase the body's immune response. Each participant will receive two vaccinations at approximately 21 days apart.
The clinical trial is expected to gather critical information to determine whether the vaccine and adjuvant are safe and effective in inducing protective immune responses.
Full Story: http://news.emory.edu/stories/
For advertising and promotion on HealthNewsDigest.com, call Mike McCurdy: 877-634-9180 or tvmike13@HealthNewsDigest.com. We have over 7,000 journalists as subscribers.